• Vinendra Parmar L. M. College of pharmacy, Ahmedabad


Objective: Teneligliptin is a novel, highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor. The objective of present study was to investigate the efficacy and safety of teneligliptin as add on therapy in patients with type 2 diabetes mellitus (T2DM) who are inadequately controlled by conventional therapy (metformin/glimepiride) in India.

Methods: Clinical study protocol was approved by Institutional Ethics Committee. T2DM patients (male/female) whose glycated haemoglobin (HbA1C) >7% were randomized to receive following group treatments viz. treatment A. Metformin/glimepiride plus add on teneligliptin 20 mg and treatment B. Metformin / Glimepiride for 24 week. Predesigned case report form (CRF) was used to collect information from the prescribing physicians regarding the efficacy and safety of teneligliptin. Efficacy variables included change in plasma blood glucose (fasting and postprandial) and glycated haemoglobin (HbA1C) from baseline to week 24. Treatment-emergent adverse events (TEAEs) were assessed.

Results:  A total 120 type 2 diabetes patients were analysed. Teneligliptin as add on therapy with metformin/glimepiride significantly reduced plasma glucose (HbA1c, fasting and postprandial) concentration as compared to conventional therapy.

Conclusion: Add on therapy with teneligliptin was found  superior over conventional-therapy in reducing plasma  glucose concentration (fasting and postprandial) and  HbA1c levels significantly in patients with T2DM. Further, it was found effective and well tolerated throughout the study period in Indian patients with type 2 diabetes mellitus who are inadequately controlled with conventional therapy.

Keywords: Teneligliptin, DDP-4 inhibitor, glycated haemoglobin (HbA1c), and type 2 diabetes mellitus (T2DM)


1. Unnikrishnan R, Anjana RM, Mohan V. Diabetes mellitus and its complications in India. Nat Rev Endocrinol [Internet]. 2016;12(6):357–70. Available from: http://dx.doi.org/10.1038/nrendo.2016.53
2. Nikhra V. Exploring Complexities of T2DM: Insulin Signaling, Resistance and Deficiency, Metabolic Links, Sexual Dimorphism and Endocrine Disruptors. Res Med Eng Sci [Internet]. 2018;5(1):1–10. Available from: http://crimsonpublishers.com/rmes/fulltext/RMES.000603.php
3. Ramachandran a, Snehalatha C, Viswanathan V. Burden of type 2 diabetes and its complications - The Indian scenario. Curr Sci. 2002;83(12):1471–6.
4. Ramachandran A, Das AK, Joshi SR, Yajnik CS, Shah S, Kumar KMP. Current status of diabetes in India and need for novel therapeutic agents. J Assoc Physicians India. 2010;58(SPEC. ISSUE):7–9.
5. Aschner P. New IDF clinical practice recommendations for managing type 2 diabetes in primary care [Internet]. Vol. 132, Diabetes Research and Clinical Practice. 2017. 169-170 p. Available from: http://linkinghub.elsevier.com/retrieve/pii/S016882271731464X
6. Gupta CN, Raghavan V, Sen S, Kothari S. Role of teneligliptin in rural India as add-on third drug in patients with type 2 diabetes mellitus. 2017;4(2):401–5.
7. Riddle MC, Bakris G, Blonde L, Boulton AJM, D ’alessio D, De Groot M, et al. Standard medical care in diabetes 2018. Diabetes Care [Internet]. 2018;41(1). Available from: http://diabetesed.net/wp-content/uploads/2017/12/2018-ADA-Standards-of-Care.pdf
8. Sharma SK, Panneerselvam A, Singh KP, Parmar G, Gadge P, Swami OC. Teneligliptin in management of type 2 diabetes mellitus. Diabetes, Metab Syndr Obes Targets Ther. 2016;9:251–60.
9. Feingold KR., et al., Oral and Injectable ( Non-insulin ) Pharmacological Agents for Type 2 Diabetes. 2019; Endotext [Internet].
10. Wang CY, Neil DL, Home P. 2020 vision – An overview of prospects for diabetes management and prevention in the next decade. Diabetes Res Clin Pract [Internet]. 2018;143:101–12. Available from: https://doi.org/10.1016/j.diabres.2018.06.007
11. Guidelines I. ICMR Guidelines for Management of Type 2 Diabetes. Pharmacological Treatment For Diabetes. 2005;Section 7:16–31.
12. Snehalatha C, Priscilla S, Nanditha A, Arun R, Satheesh K, Ramachandran A. Metformin in prevention of type 2 diabetes. J Assoc Physicians India. 2018;66(March):55–8.
13. Kim Y, Kang ES, Jang HC, Kim DJ, Oh T, Kim ES, et al. Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial. Diabetes, Obes Metab [Internet]. 2018; Available from: http://doi.wiley.com/10.1111/dom.13566
14. Kim YG, Hahn S, Oh TJ, Park KS, Cho YM. Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: A systematic review and meta-analysis. Diabetes, Obes Metab. 2014;16(10):900–9.
15. Mohammed R, Ahmed I, Banu A. Efficacy of teneligliptin in type 2 diabetes mellitus. 2016;4(10):4607–10.
16. Kishimoto M. Teneligliptin: A DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes, Metab Syndr Obes Targets Ther. 2013;6:187–95.
17. Yoshida T, Akahoshi F, Sakashita H, Kitajima H, Nakamura M, Sonda S, et al. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3- methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl] thiazolidine): A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for. Bioorganic Med Chem [Internet]. 2012;20(19):5705–19. Available from: http://dx.doi.org/10.1016/j.bmc.2012.08.012
18. Nakamaru Y, Hayashi Y, Ikegawa R, Kinoshita S, Madera BP, Gunput D, et al. Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans. Xenobiotica. 2014;44(3):242–53.
19. Rodbard H, Jellinger P, Davidson J, Einhorn D, Garber A, Grunberger G, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control. Endocr Pract [Internet]. 2009;15(6):540–59. Available from: http://journals.aace.com/doi/abs/10.4158/EP.15.6.540
20. Yesudian CAK, Grepstad M, Visintin E, Ferrario A. The economic burden of diabetes in India: A review of the literature. Global Health. 2014;10(1):1–18.
21. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Robert EA, Janecek E, et al., A method for estimating the probability of adverse drug reaction. Clin Pharmacol Ther. 1981; 30:239-45.
22. Chandra P, Gogate B, Gogate P, Thite N, Mutha A, Walimbe A. Economic Burden of Diabetes in Urban Indians. Open Ophthalmol J [Internet]. 2015;8(1):91–4. Available from: http://benthamopen.com/ABSTRACT/TOOPHTJ-8-91
23. Li X, Huang X, Bai C, Qin D, Cao S, Mei Q. Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus?: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2018;9(May).
24. Bajaj S. RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017 [Internet]. Vol. 38, International Journal of Diabetes in Developing Countries. 2018. 1-115 p. Available from: http://link.springer.com/10.1007/s13410-018-0604-7
25. Takeda K, Sawazaki H, Takahashi H, Yeh YS, Jheng HF, Nomura W, et al. The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin enhances brown adipose tissue function, thereby preventing obesity in mice. FEBS Open Bio. 2018;4:1782–93.
26. Oguma T, Kuriyama C, Nakayama K, Matsushita Y, Yoshida K, Kiuchi S, et al. The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats. J Pharmacol Sci [Internet]. 2015;127(4):456–61. Available from: http://dx.doi.org/10.1016/j.jphs.2015.03.006
27. Kadowaki T, Kondo K, Sasaki N, Miyayama K, Yokota S, Terata R, et al. Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period. Expert Opin Pharmacother. 2017;18(13):1291–300.
28. Kim MK, Rhee EJ, Han KA, Woo AC, Lee MK, Ku BJ, et al. Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: A 16-week, randomized, double-blind, placebo-controlled phase III trial. Diabetes, Obes Metab. 2015;17(3):309–12.
29. Salvo F, Moore N, Arnaudl M, Robinson P, Raschi E, De Ponti F, et al. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: Systematic review and meta-analysis. BMJ. 2016;353:1–9.
30. Moon MK, Hur KY, Ko SH, Park SO, Lee BW, Kim JH, et al. Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus. Korean J Intern Med. 2017;32(6):974–83.
31. Wu S, Chai S, Yang J, Cai T, Xu Y, Yang Z, et al. Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis. Clin Ther [Internet]. 2017;39(9):1780–1789.e33. Available from: http://dx.doi.org/10.1016/j.clinthera.2017.07.036
11 Views | Downloads
How to Cite
Parmar, V. “EFFICACY AND SAFETY OF TENELIGLIPTIN AS ADD ON THERAPY TO CONVENTIONAL THERAPY IN INDIAN PATIENTS WITH TYPE 2 DIABETES MELLITUS”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 12, no. 12, Oct. 2019, https://innovareacademics.in/journals/index.php/ajpcr/article/view/35952.
Original Article(s)